Apremilast: all 117 studies that test it

Page 2 of 2. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.

• Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque PsoriasisStatus unknownNCT03453190Phase 4
• Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing AlopeciaStatus unknownNCT03422640Phase 4
• Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic ArthritisStatus unknownNCT03191539Phase 3
• An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular EczemaCompletedNCT03160248Phase 2
• Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of VitiligoCompletedNCT03123016Phase 2
• Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative HidradenitisCompletedNCT03049267Phase 2
• Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGOCompletedNCT03036995Phase 2
• Single Center Study of Apremilast for the Treatment of Hidradenitis SuppurativaCompletedNCT02695212Phase 2
• Treatment With Apremilast in Patients With Psoriatic ArthritisWithdrawnNCT02558361Phase 4
• The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)CompletedNCT01250548Phase 2
• Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARAWithdrawnNCT01204138Phase 2
• Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand OsteoarthritisCompletedNCT01200472Phase 2
• Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic TherapyWithdrawnNCT01200264Phase 2
• Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen PlanusStatus unknownNCT01041625Phase 2
• Apremilast Therapy for Acute Gouty ArthritisWithdrawnNCT00997581Phase 2
• Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type PsoriasisCompletedNCT00606450Phase 2
• Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type PsoriasisCompletedNCT00604682Phase 2

← Apremilast overview